ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
An integrated approach combining computational analyses and experimental validation deciphers the mechanism and active substance basis of Huazhuo Ningfu decoction in treating psoriasis.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
This study aims to elucidate the mechanism of HZD in treating psoriasis and identify its active components through a comprehensive approach combining tandem mass tag (TMT)-based quantitative proteomics with machine learning and molecular docking analysis. An integrated strategy was employed, combining tandem mass tag (TMT)-based quantitative proteomics and machine learning to identify critical targets in an imiquimod (IMQ)-induced mouse model of psoriasis. Key findings were then experimentally validated using the human immortalized keratinocyte (HaCaT) cell model and HZD-treated mice through techniques including 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), quantitative real-time PCR (qPCR), Western blot (WB), and immunofluorescence (IF). Furthermore, molecular docking and dynamics simulations were utilized to investigate interactions between HZD's bioactive components and the identified targets. Our findings demonstrate that HZD alleviates psoriasis primarily by inhibiting the Notch signaling pathway and upregulating keratin 77 (KRT77), thereby normalizing keratinocyte function. The identification of nuciferine as a key multi-target constituent, along with its structural analogs, provides a pharmacological basis for HZD's efficacy and reveals promising leads for novel psoriasis therapeutics.
Indexed as
Identifiers
41348204What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.